Resource Logo
NLM AIDSLINE

Seroconversion to dual reactivity among HIV-1 and HIV-2 seropositive women in Abidjan, Cote d'Ivoire.




 

Int Conf AIDS. 1994 Aug 7-12;10(1):316 (abstract no. PC0195). Unique

OBJECTIVE: To assess the rate of seroconversion from HIV-negative (HIV-N) to HIV-1 or HIV-2 seropositivity and from HIV-1 or HIV-2 seropositivity to dual reactivity (HIV-D) in a cohort of women enrolled in a study of perinatal HIV transmission in Abidjan, Cote d'Ivoire. METHODS: From September 1990 to August 1992, HIV-1, HIV-2, and HIV-N women were enrolled at delivery and followed until January 1994. Six-monthly blood samples were screened for HIV antibodies by EIA and confirmed by a synthetic peptide-based test (Peptilav) or Western blot. HIV serotype (HIV-1, HIV-2, or HIV-D) was determined by Peptilav, and seroconversion (SC) was defined as a change in Peptilav result. Lymphocyte subtyping was performed. TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: SC to dual reactivity occurs at similar rates in HIV-1 and HIV-2 women, occurs at higher rates than does SC from HIV-N to HIV-1 or HIV-2 seropositivity, and tends to be associated with more advanced immunosuppression. These data suggest that immunosuppressed HIV seropositive women may be more susceptible to HIV-1 or HIV-2 infection than are seronegative women and/or that dual reactivity may be a marker for immunosuppression. Virologic testing will help to investigate these two possibilities.

Cohort Studies Female Human HIV Infections/IMMUNOLOGY *HIV Seropositivity HIV-1/*IMMUNOLOGY HIV-2/*IMMUNOLOGY ABSTRACT



 




Information in this article was accurate in December 30, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.